Back to Results
First PageMeta Content
Intel Viiv / Integrase inhibitors / Organofluorides / Pfizer / Biology / Pharmacology / Dolutegravir / Shionogi / Pharmaceutical industry / Pharmaceutical sciences / ViiV Healthcare / GlaxoSmithKline


Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav
Add to Reading List

Document Date: 2014-11-03 11:26:24

Open Document

File Size: 94,97 KB

Share Result on Facebook
UPDATE